Home / Europe / Czech Republic / Life Sciences & Healthcare

Life Sciences & Healthcare

Our Prague team regularly advises pharmaceutical companies and medical device manufacturers on a range of commercial and regulatory issues.

We work with and have established long-term relationships with the top 100 lifesciences companies in the areas of pharmaceuticals, medical devices, biotechnology, agriculture and food, including the top 20 global pharmaceutical companies and nine out of the top ten global medical device companies.

Our lifesciences teams in Central and Eastern Europe advise leading global business groups in the sector on transactions, commercial agreements, compliance, investigations and litigation, very often across multiple jurisdictions in the region and beyond. We can help you to navigate the regulatory landscape and to ensure compliance with both local laws and global policies.

With over 480 international specialist lawyers across CMS and the support of the Lifesciences Asia-Pacific Network (LAN), we understand the scientific and commercial as well as the legal imperatives affecting your lifesciences business. Our experts, many of whom have worked in-house in your sector, have developed a shared capability in the areas of pharmaceuticals, biotechnology, medical devices and diagnostics.

With active memberships in major industry associations such as the ABPI, ABHI, BIVDA, PAGB, EUCOMED and EFPIA, we help shape the legal frameworks impacting the lifesciences sector. We regularly advise our clients on their day-to-day operational needs such as support with advertisement and promotion of medicine, public sector procurement, pricing and reimbursement, patent enforcement, commercial and clinical trial agreements as well as regulatory advice.


Feed

19/05/2022
Can­nabis law and le­gis­la­tion in Czech Re­pub­lic
Med­ic­al use Grow­ing can­nabis for med­ic­al use is al­lowed upon ob­tain­ing a li­cence to plant can­nabis plants and a per­mis­sion to dis­pose of ad­dict­ive sub­stances and products re­lated to med­ic­al can­nabis...
08/04/2022
The Pro­posed Dir­ect­ive on Cor­por­ate Sus­tain­ab­il­ity Due Di­li­gence – a step...
The Pro­posed Dir­ect­ive on Cor­por­ate Sus­tain­ab­il­ity Due Di­li­gence (the “CSDD Pro­pos­al”), pub­lished on 23 Feb­ru­ary 2022, aims to im­pose ob­lig­a­tions on com­pan­ies, their sub­si­di­ar­ies and their value chains...
05/04/2022
Re­cent up­dates to the EPO Guidelines for Ex­am­in­a­tion rel­ev­ant to in­ven­tions...
An amended ver­sion of the EPO Guidelines for Ex­am­in­a­tion entered in­to force on 1 March 2022, su­per­sed­ing the edi­tion of March 2021. Here we re­view the up­dates rel­ev­ant to in­ven­tions in the field of bi­o­tech­no­logy...
03/03/2022
Ad­verse ef­fects of drugs and vac­cines in Czech Re­pub­lic
1. Drug ad­verse ef­fects: kinds of re­spons­ib­il­ity 1.1 Which are the main kinds of re­spons­ib­il­ity (con­trac­tu­al, in tort, crim­in­al) of the fol­low­ing sub­jects with re­spect to ad­verse drugs re­ac­tions? A...
Comparable
17/02/2022
Sig­ni­fic­ant Con­sulta­tion on pro­posed re­vi­sions to REACH
Un­til 15 April 2022, the European Com­mis­sion (“EC”) is con­sult­ing on pro­posed re­vi­sions of REACH, (Reg­u­la­tion (EC) No 1907/2006 as amended), the corner­stone of EU chem­ic­als reg­u­la­tion. REACH aims...
02/02/2022
Changes to the Czech Pub­lic Health In­sur­ance Act
In Septem­ber 2021, the Czech Par­lia­ment ad­op­ted a long-awaited, ex­tens­ive amend­ment to the Pub­lic Health In­sur­ance Act (the Amend­ment, the Act), which be­came ef­fect­ive on 1 Janu­ary 2022. The Amend­ment...
01/02/2022
UPC: Is it fi­nally here?
New tem­por­ary pro­vi­sions at the European Pat­ent Of­fice re­lat­ing to the Unit­ary Pat­ent The European Pat­ent Of­fice (EPO) is­sued 3 new no­tices on 19 Janu­ary 2022 about the Unit­ary Pat­ent. They are:...
27/01/2022
Schrems II: Re­ac­tions to the judge­ment and the su­per­vis­ory au­thor­it­ies'...
“Schrems II”: Opin­ions of the su­per­vis­ory au­thor­it­ies on Schrems II and re­com­mend­a­tions on the im­ple­ment­a­tion of the judge­ment in in­ter­na­tion­al data trans­fers On 16 Ju­ly 2020, the Court of Justice...
10/01/2022
CMS Next
What’s next? In a world of ever-ac­cel­er­at­ing change, stay­ing ahead of the curve and know­ing what’s next for your busi­ness or sec­tor is es­sen­tial.At CMS, we see ourselves not only as your leg­al ad­visers but also as your busi­ness part­ners. We work to­geth­er with you to not only re­solve cur­rent is­sues but to an­ti­cip­ate fu­ture chal­lenges and in­nov­ate to meet them.With our latest pub­lic­a­tion, CMS Next, our ex­perts will reg­u­larly of­fer you in­sights in­to and fresh per­spect­ives on a range of is­sues that busi­nesses have to deal with – from ESG agen­das to re­struc­tur­ing after the pan­dem­ic or fa­cing the di­git­al trans­form­a­tion. We will also share with you more about the work that we are do­ing for our cli­ents, help­ing them in­nov­ate, grow and mit­ig­ate risk.To be able to provide you with the best sup­port, we im­merse ourselves in your world to un­der­stand your leg­al needs and chal­lenges. However, it is equally im­port­ant that you know who we are and how we can work with you. So, we in­vite you to meet our ex­perts and catch a glimpse of what is hap­pen­ing in­side CMS.En­joy read­ing this pub­lic­a­tion, which we will up­date reg­u­larly with new con­tent.CMS Ex­ec­ut­ive Team
13/12/2021
In­crease in the law­ful amount of THC in hemp to 1% in the Czech Re­pub­lic
The world is wit­ness­ing an in­crease in the pop­ular­ity of hemp products, with many coun­tries re­act­ing by ad­just­ing their na­tion­al le­gis­la­tion ac­cord­ingly. This par­tic­u­larly con­cerns those laws which gov­ern...
01/12/2021
A piece of pat­ent his­tory has been made con­cern­ing pat­entab­il­ity of com­puter...
In March 2021 the En­larged Board of Ap­peal of the European Pat­ent Of­fice answered ques­tions con­cern­ing pat­entab­il­ity of com­puter soft­ware sim­u­la­tions in case G1/19.  A Tech­nic­al Board of Ap­peal has now...
24/11/2021
On the Pulse
Wel­come to CMS ‘On the Pulse’ video/pod­cast series for all Life Sci­ences & Health­care pro­fes­sion­als – leg­al, com­pli­ance, reg­u­lat­ory